Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of neurological disorders in Australia. It primarily focuses on the Alzheimers, Parkinsons, and Huntingtons diseases, as well as various cancer and age-related macular degeneration. The companys product line includes PBT2, which is in Phase IIb clinical trials for the treatment of Alzheimers disease, as well as in Phase IIa clinical trials to treat Huntingtons disease. Its preclinical products comprise PBT434 for the treatment of Alzheimers disease; and PBT519 to treat brain cancer. The company was formerly known as Prana Corporation Ltd. and changed its name to Prana Biotechnology Limited in January 2000. Prana Biotechnology Limited was founded in 1997 and is based in Parkville, Australia.
Market Trend Signal
Stock Analysis Software and Trading System